Early diagnosis and predictors of malignancy of adnexal masses

Current Opinion in Obstetrics and Gynecology

Volumn 18, Issue 1, 2006, Pages 14-19

  Murta, Eddie F C ^a   Nomelini, Rosekeila S ^a  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

Adnexal mass; Biomarkers; Ovarian cancer; Pelvic examination; Ultrasound

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 72-4 ANTIGEN;

ADNEXA DISEASE; CANCER STAGING; CANCER SURVIVAL; COLOR ULTRASOUND FLOWMETRY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; MATHEMATICAL MODEL; OVARY CANCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TRANSVAGINAL ECHOGRAPHY; TREATMENT PLANNING;

ADNEXAL DISEASES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MASS SCREENING; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646489318     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000192967.67567.e9     Document Type: Review

References (50)

1. Rubin SC. Surgery for ovarian cancer. In: Ovarian Cancer. Edited by Ozols RF. Hematol Oncol Clin North Am 1992; 851-865.
2. Hensley ML, Spriggs DR. Cancer screening: How good is good enough? J Clin Oncol 2004; 22:4037-4039. A brief but current analysis of screening for ovarian cancer.
3. Padilla LA, Radosevich DM, Milad MP. Limitations on the pelvic examination for evaluation of the female pelvic organs. Gynecol Obstet 2005; 88:84-88. A prospective cohort study showing factors influencing an accurate pelvic examination for uterine and adnexal assessment.
4. Murta EFC, Silva CS, Gomes RAS, et al. Ultrasonography criteria and tumor marker assay are good procedures for the diagnosis of ovarian neoplasia in preselected outpatients. Eur J Gynaec Oncol 2004; 25:707-712. An interesting demonstration of combining imaging methods and tumor markers in the diagnosis of ovarian neoplasia.
5. U.S. Preventive Services Task Force. Screening for ovarian cancer: Recommendation statement. Ann Fam Med 2004; 2:260-262.
6. Fishman D, Cohen L, Blank SV. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 2005; 192:1214-1222. A review of the value of ultrasonography in screening for ovarian cancer. It illustrates the limited application of ultrasound as an independent method for detecting early-stage epithelial ovarian cancer.
7. Lee H, Park G, Jung JH, et al. Diagnostic approach using the expression profiling of the p53 tumor suppressor gene and its related proteins in ovarian epithelial tumors. Int J Gynecol Cancer 2005; 15:453-461. A description of expression profiles of p53 and their usefulness in making a differential diagnosis between benign, borderline, and malignant ovarian tumors.
8. Huddleston HG, Wong KK, Welch WR, et al. Clinical applications of microarray technology: Creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 2005; 96:77-83. A description of a promising biomarker, CKB, using the technology of gene-expression microarray.
9. Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004; 22:3330-3339.
10. Robertson DM, Pruysers E, Burger HG, et al. Inhibins and ovarian cancer. Mol Cell Endocrinol 2004; 225:65-71. This is a study of the feasibility of inhibins in assessing and monitoring the recurrence of ovarian cancer.
11. Woo MMM, Gilks CB, Verhage HG, et al. Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. Gynecol Oncol 2004; 93:315-319.
12. Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch Gynecol Obstet 2004; 270:151-156. This study determined gonadotropin levels in serum and cyst fluid in ovarian epithelial tumors.
13. McIntosh MW, Drescher C, Karlan B, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004; 95:9-15. A recent evaluation of a composite marker that combines CA 125 and a soluble mesothelin-related marker in a screening program.
14. Rapkiewicz AV, Espina V, Petricoin EF III, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer 2004; 40:2604-2612. A review of tumor markers for the detection of ovarian cancer.
15. Varras M. Benefits and limitations of ultrasonographic evaluation of uterine adnexal lesions in early detection of ovarian cancer. Clin Exp Obstet Gynecol 2004; 31:85-98.
16. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3:355-366.
17. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000; 77:350-356.
18. Posadas EM, Davidson B, Kohn EC. Proteomics and ovarian cancer: implications for diagnosis and treatment: A critical review of the recent literature. Curr Opin Oncol 2004; 16:478-484. A precise review of proteomics. This study shows their applicability to ovarian cancer.
19. Li L, Tang H, Wu Z, Gong J, et al. Data mining techniques for cancer detection using serum proteomic profiling. Artif Intell Med 2004; 32:71-83. A review showing an approach to serum proteomics in ovarian cancer.
20. Ransohoff DF. Lessons from controversy: Ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005; 97:315-319. An analysis of how to study serum proteomics and ovarian cancer.
21. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Cancer Res 2004; 10:3291-3300.
22. Minaretzis D, Tsionou C, Tziortziotis D, et al. Ovarian tumors: Prediction of the probability of malignancy by using patient's age and tumor morphologic features with a logistic model. Gynecol Obstet Invest 1994; 38:140-144.
23. Knudsen UB, Tabor A, Mosgaard B, et al. Management of ovarian cysts. Acta Obstet Gynecol Scand 2004; 83:1012-1021. A review of diagnostic methods for discriminating between benign and malignant cysts. Combined techniques improve the results from single methods.
24. Tavares-Murta BM, Cunha FQ, Miranda R, et al. Differential tumor microenvironment in human ovarian cystic tumors. Tumori 2004; 90:491-497. A recent study of differentiating between benign tumors or other gynecological alterations using cystic-fluid analysis.
25. Im SS, Gordon AN, Buttin BM, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005; 105:35-41. An analysis of factors included in the guidelines of surgically evaluated women with adnexal masses.
26. Szpurek D, Moszyniki R, ZietkowiakW, et al. An ultrasonographic morphological index for prediction of ovarian tumor malignancy. Eur Gynaecol Oncol 2005:51-54. A recent demonstration of Doppler ultrasonography for the diagnosis of ovarian cancer. Doppler index results help in the decision on the best surgical treatment.
27. Guerriero S, Ajossa S, Garau N, et al. Ultrasonography and color Doppler-based triage for adnexal masses to provide the most appropriate surgical approach. Am J Obstet Gynecol 2005; 192:401-406. This study shows the value of color Doppler ultrasonography in patients with an adnexal mass.
28. Bromley B, Goodman H, Benacerraf BR. Comparison between sonographic morphology and Doppler waveform for the diagnosis of ovarian malignancy. Obstet Gynecol 1994; 83:434-437.
29. Valentin L, Sladkevicius P, Marsal K. Limited contribution of Doppler velocimetry to the differential diagnosis of extrauterine pelvic tumors. Obstet Gynecol 1994; 83:425-433.
30. Daskalakis G, Kalmantis K, Skartados N, et al. Assessment of ovarian tumors using transvaginal color Doppler ultrasonography. Eur J Gynaec Oncol 2004; 25:594-595. A study showing transvaginal ultrasonography in combination with color Doppler scanning in the differentiation of ovarian tumors.
31. Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: The contribution of Doppler ultrasound. Obstet Gynecol 1999; 14:338-347.
32. Fleisher AC, Milam MR, Crispens MA, Shappell HW. Sonographic depiction of intratumoral vascularity with 2- and 3-dimensional color Doppler techniques. J Ultrasound Med 2005; 24:533-537. A demonstration of three-dimensional color Doppler sonography in distinguishing benign from malignant ovarian masses.
33. Marret H, Sauget S, Giraudeau B, et al. Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med 2004; 23:1629-1639. A study of the feasibility of contrast-enhanced sonography in the diagnosis of the adnexal mass.
34. Grab D, Flock F, Stöhr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000; 77:454-459.
35. Alcázar JL, Castillo G. Comparison of 2-dimensional and 3-dimensional power-Doppler imaging in complex adnexal masses for the prediction of ovarian cancer. Obstet Gynecol 2005; 192:807-812. A recent demonstration of the diagnostic performance of two-dimensional and three-dimensional power-Doppler ultrasonography for discriminating benign from malignant complex adnexal masses.
36. Moss EL, Hollingworth J, Reynolds TM. The role of CA 125 in clinical practice. J Clin Pathol 2005; 58:308-312. A study illustrating the usefulness of CA 125 and its contribution to individual patient management.
37. Menon U, Jacobs I. Ovarian cancer screening in the general population. Ultrasound Obstet Gynecol 2000; 15:350-353.
38. Conrads TP, Fusaro VA, Ross S, et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 2004; 11:163-178.
39. Roupa Z, Faros E, Raftopoulos V, et al. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening. In Vivo 2004; 18: 831-836. The combination of transvaginal ultrasonography score and serum CA 125 provides an accurate prediction of detecting ovarian cancer.
40. Mancuso A, De Vivo A, Triolo O, Irato S. The role of transvaginal ultrasonography and serum CA 125 assay combined with age and hormonal state in the differential diagnosis of pelvic masses. Eur J Gynecol Oncol 2004; 25:207-210. An assessment of CA 125 and ultrasonography in the diagnosis of ovarian cancer. These methods were evaluated alone and in combination with clinical parameters.
41. Kumar P, Rehani MM, Kumar L, et al. Tumor marker CA-125 as an evaluator and response indicator in ovarian cancer: its quantitative correlation with tumor volume. Med Sci Monit 2005; 11:84-89. This study shows the correlation between CA 125 level and ovarian tumor volume before and during chemotherapy.
42. Skates SJ, Horick N, Yu Y, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004; 22:4059-4066. A recent study showing the performance of several more efficient approaches to combining information in terms of multiple markers in ovarian cancer: logistic regression, classification trees, and mixture-discriminant analysis.
43. Milojkovic M, Hrgovic Z, Hrgovic I, et al. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis. Arch Gynecol Obstet 2004; 269:176-180.
44. Woolas RP, Conaway FX, Jacobs IJ. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995; 59:111-116.
45. Duffy MJ. Evidence for the clinical use of tumour markers. Ann Clin Biochem 2004; 41:370-377. A review of the clinical relevance of tumor marker assay in the management of ovarian cancer.
46. Cheng L, Thomas A, Roth LM, et al. OCT4: A novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol 2004; 28:1341-1346. A description of OCT4 , a novel biomarker used for dysgerminoma.
47. Adib TR, Henderson S, Perrett C, et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004; 90:686-692.
48. Drapkin R, Crum CP, Hecht JL. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: Evidence for a link between epithelial phenotype and neoplasia. Hum Pathol 2004; 35:1014-1021.
49. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:981-987. A promising approach for the detection of ovarian cancer using a panel of serum cytokines and CA 125.
50. Timmerman D. The use of mathematical models to evaluate pelvic masses: Can they beat an expert operator? Best Pract Res Clin Obstet Gynecol 2004; 18:91-104. A practice review of mathematical models to evaluate pelvic masses.